Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial. Conference

Mehta, MP, Gervais, R, Chabot, P et al. (2006). Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial. . JOURNAL OF CLINICAL ONCOLOGY, 24(18), 367S-367S.

Industry Collaboration International Collaboration

cited authors

  • Mehta, MP; Gervais, R; Chabot, P; Shapiro, WR; Patchell, RA; Glantz, MJ; Recht, L; Phan, S; Smith, JA; Renschler, MF

sustainable development goals

authors

date/time interval

  • June 2, 2006 -

publication date

  • June 20, 2006

webpage

published in

keywords

  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

Location

  • Atlanta, GA

Conference

  • 42nd Annual Meeting of the American-Society-of-Clinical-Oncology

publisher

  • AMER SOC CLINICAL ONCOLOGY

start page

  • 367S

end page

  • 367S

volume

  • 24

issue

  • 18